FN3 domain-siRNA conjugates and uses thereof
The present disclosure relates to compositions, such as siRNA molecules and FN3 domains conjugated to the same, as well as methods of making and using the molecules.
1. A composition comprising a siRNA molecule comprising a sense strand and antisense strand, wherein:
the sense strand comprises a sequence of SEQ ID NO: 12, 18, 24, 30, 34, 152, 154, 164, 170, 182, 212, 214, or 216; and
the anti-sense strand comprises a sequence of SEQ ID NO: 13, 19, 25, 31, 35, 153, 155, 165, 171, 183, 213, 215, or 217.
2. The composition of claim 1 , wherein the siRNA further comprises a linker, wherein the linker is covalently attached to the sense strand or the anti-sense strand of the siRNA.
3. The composition of claim 2 , wherein the siRNA is linked to one or more FN3 domains.
4. The composition of claim 2 , wherein the linker is covalently attached to the 3′ end of the sense strand.
5. The composition of claim 4 , wherein the siRNA is linked to one or more FN3 domains.
6. The composition of claim 2 , wherein the linker comprises a compound having the formula of:
7. The composition of claim 6 , wherein the siRNA is linked to one or more FN3 domains.
8. The composition of claim 1 , wherein the siRNA further comprises a vinyl phosphonate, wherein the vinyl phosphonate is covalently attached to the sense strand or the anti-sense strand of the siRNA.
9. The composition of claim 8 , wherein the siRNA is linked to one or more FN3 domains.
10. The composition of claim 8 , wherein the vinyl phosphonate is covalently attached to the 5′ end of the antisense strand.
11. The composition of claim 10 , wherein the siRNA is linked to one or more FN3 domains.
12. The composition of claim 1 , wherein the siRNA further comprises a linker covalently attached to the 3′ end of the sense strand and a vinyl phosphonate covalently attached to the 5′ end of the antisense strand.
13. The composition of claim 12 , wherein the siRNA is linked to one or more FN3 domains.
14. The composition of claim 12 , wherein the siRNA molecule comprises:
a sense strand of SEQ ID NO: 188 and an antisense strand of SEQ ID NO: 189;
a sense strand of SEQ ID NO: 190 and an antisense strand of SEQ ID NO: 191;
a sense strand of SEQ ID NO: 192 and an antisense strand of SEQ ID NO: 193;
a sense strand of SEQ ID NO: 196 and an antisense strand of SEQ ID NO: 197;
a sense strand of SEQ ID NO: 206 and an antisense strand of SEQ ID NO: 207; or
a sense strand of SEQ ID NO: 210 and an antisense strand of SEQ ID NO: 211.
15. The composition of claim 12 , wherein
the sense strand comprises a sequence of SEQ ID NO: 188, 190, 192, 196, 206, or 210; and
the anti-sense strand comprises a sequence of SEQ ID NO: 189, 191, 193, 197, 207, or 211.
16. The composition of claim 15 , wherein the siRNA is linked to one or more FN3 domains.
17. The composition of claim 1 , wherein the siRNA molecule comprises:
a sense strand of SEQ ID NO: 12 and an antisense strand of SEQ ID NO: 13;
a sense strand of SEQ ID NO: 18 and an antisense strand of SEQ ID NO: 19;
a sense strand of SEQ ID NO: 24 and an antisense strand of SEQ ID NO: 25;
a sense strand of SEQ ID NO: 30 and an antisense strand of SEQ ID NO: 31;
a sense strand of SEQ ID NO: 34 and an antisense strand of SEQ ID NO: 35;
a sense strand of SEQ ID NO: 152 and an antisense strand of SEQ ID NO: 153;
a sense strand of SEQ ID NO: 154 and an antisense strand of SEQ ID NO: 155;
a sense strand of SEQ ID NO: 164 and an antisense strand of SEQ ID NO: 165;
a sense strand of SEQ ID NO: 170 and an antisense strand of SEQ ID NO: 171;
a sense strand of SEQ ID NO: 182 and an antisense strand of SEQ ID NO: 183;
a sense strand of SEQ ID NO: 212 and an antisense strand of SEQ ID NO: 213;
a sense strand of SEQ ID NO: 214 and an antisense strand of SEQ ID NO: 215; or
a sense strand of SEQ ID NO: 216 and an antisense strand of SEQ ID NO: 217.
18. The composition of claim 17 , wherein the siRNA is linked to one or more FN3 domains.
19. The composition of claim 1 , wherein the siRNA is linked to one or more FN3 domains.
20. A pharmaceutical composition comprising a composition of claim 19 .
21. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject the composition of claim 19 .
22. A method of reducing the expression of KRAS in a cell, the method comprising contacting the cell with the composition of claim 19 .
23. A method of delivering a siRNA that targets KRAS to a cell in a subject, the method comprising administering to the subject a pharmaceutical composition comprising the composition of claim 19 .
24. A composition having a formula of (X1)n-(X2)q-(X3)y-L-X4, wherein:
X1 is a first FN3 domain;
X2 is second FN3 domain;
X3 is a third FN3 domain or half-life extender molecule;
L is a linker; and
X4 is a nucleic acid molecule,
wherein n, q, and y are each independently 0 or 1, and
wherein the nucleic acid molecule comprises a siRNA molecule having:
a sense strand comprising a sequence of SEQ ID NO: 12, 18, 24, 30, 34, 152, 154, 164, 170, 182, 188, 190, 192, 196, 206, 210, 212, 214, or 216; and
an anti-sense strand comprising a sequence of SEQ ID NO: 13, 19, 25, 31, 35, 153, 155, 165, 171, 183, 189, 191, 193, 197, 207, 211, 213, 215, or 217.
25. The composition of claim 24 , wherein L comprises a compound having the formula of:
26. The composition of claim 24 , wherein each of X1, X2, or X3 is linked by a linker, wherein the linker comprises a sequences of SEQ ID NO: 369, 370, 371, 372, 373, 374, 375, or 376.
27. The composition of claim 24 , wherein X1 comprises a sequence of SEQ ID NO: 300-335, 337-368, 377-392, or 395-623.
28. The composition of claim 24 , wherein X2 comprises a sequence of SEQ ID NO: 300-335, 337-368, 377-392, or 395-623.
29. The composition of claim 24 , wherein X3 comprises a sequence of SEQ ID NO: 300-335, 337-368, 377-392, or 395-623.
30. A composition having a formula A1-B1, wherein A1 has a formula of C1-L1-XS and B1 has a formula of XAS-L2-F1, wherein:
C1 is a polymer;
L1 and L2 are each, independently, a linker;
XS is a 5′ to 3′ oligonucleotide sense strand of a double stranded siRNA molecule comprising a sequence of SEQ ID NO: 12, 18, 24, 30, 34, 152, 154, 164, 170, 182, 188, 190, 192, 196, 206, 210, 212, 214, or 216;
XAS is a 3′ to 5′ oligonucleotide antisense strand of a double stranded siRNA molecule comprising a sequence of SEQ ID NO: 13, 19, 25, 31, 35, 153, 155, 165, 171, 183, 189, 191, 193, 197, 207, 211, 213, 215, or 217; and
F1 is a polypeptide comprising at least one FN3 domain.
31. The composition of claim 30 , wherein A1-B1 has a formula of:
32. The composition of claim 30 , wherein F1 comprises a polypeptide having a formula of (X1)n-(X2)q-(X3)y,
wherein X1 is a first FN3 domain; X2 is second FN3 domain; X3 is a third FN3 domain or half-life extender molecule; and
wherein n, q, and y are each independently 0 or 1, provided that at least one of n, q, and y is 1.
33. The composition of claim 32 , wherein X1 comprises a sequence of SEQ ID NO: 300-335, 337-368, 377-392, or 395-623.
34. The composition of claim 32 , wherein X2 comprises a sequence of SEQ ID NO: 300-335, 337-368, 377-392, or 395-623.
35. The composition of claim 32 , wherein X3 comprises a sequence of SEQ ID NO: 300-335, 337-368, 377-392, or 395-623.
36. The composition of claim 30 , wherein the linker comprises a sequence of SEQ ID NO: 369, 370, 371, 372, 373, 374, 375, or 376.